SUMMARY Determination of plasma concentration of pyridostigmine in 20 myasthenic patients on maintenance therapy revealed rather small intraindividual variations within a dose interval. The predose concentration varied considerably between different patients and up to seven fold in patients on the same daily dose. No pharmacokinetic interaction between pyridostigmine and neostigmine was found in five patients studied. In six patients the decrement in the deltoid muscle was studied in parallel with determination of the plasma concentrations following administration of pyridostigmine or neostigmine. In these patients the existence of a "bell-shaped" dose response curve is suggested with the maximal effect at a concentration of 30-60 ng/ml for pyridostigmine and 5-15 ng/ml for neostigmine.
The introduction of steroids and immunosuppressive drugs in the treatment of myasthenia gravis has not changed the role of cholinseterase inhibitors as the basic medical therapy of the disease. Among these drugs pyridostigmine and neostigmine are those commonly prescribed in Sweden. Therapy is in most instances pursued with pyridostigmine but sometimes a combination of the two drugs is used.
The first study on the pharmacokinetics of pyridostigmine using a gas-chromatographic method was published in 1976.' A more selective analytical procedure was developed by Chan et a12 and used in the study of the pharmacokinetics of pyridostigmine3 and neostigmine.45 With this method, however, it is not possible to measure the two drugs simultaneously. The development of a more sensitive and selective analytical procedure using gas chromatography-mass spectrometry with deuterated internal standards enabled us to study the basic pharmacokinetics of pyridostigmine and neostigmine.67 The pharmacokinetic profiles of the two drugs were found to be fundamentally similar with a terminal half-life in plasma of about 1-4 and 0*9 hours for pyridostigmine and neostigmine, respec-tively. The oral bioavailability was higher for pyridostigmine (7.6%) than for neostigmine(2%), which in combination with the longer terminal halflife might offer some pharmacokinetic advantages in maintenance therapy.
The aim of the present study was to elucidate the clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. The main objectives have been: (1) to establish the relation between daily dose and steady-state plasma concentration, (2) to investigate if combination therapy with neostigmine and pyridostigmine results in pharmacokinetic interactions, (3) to relate the pharmacokinetics of pyridostigmine and neostigmine to the effect as measured by improvement of decrement of muscle response.
Material and methods
Blood sampling and analysis of pyridostigmine and neosnigmine Blood samples were collected at regular intervals and immediately cooled on ice and plasma was separated. Two ml of plasma were transferred to a glass tube and in the case of neostigmine deuterated intemal standard (d6-neo) was added before the samples were stored in the freezer (-18°C) to compensate for the in vitro degradation earlier demonstrated.6 Pyridostigmine and neostigmine were quantitated after ion-pair extraction and determination by gas chromatography-mass spectrometry with chemical ioniza-929
Aquilonius, Eckernds, Hartvig, Lindstrom, Osterman, Stdlberg Interaction between neostigmine and pyridostigmine In five patients a possible pharmacokinetic interaction between the two drugs was investigated. The patients were given oral neostigmine on several occasions for at least one day and on the next day five blood samples were collected regularly during a dosage interval. Thereafter the two drugs were administered together for three days and blood samples were taken as above. Neostigmine was then withdrawn and the patients were treated with pyridostigmine only. After one to three days a new series of blood samples was taken during a dosage interval. In the investigation period no other medications were given.
Decrement of muscle response at repetitive nerve stimulation
In six patients the improvement of decrement was studied after administration of pyridostigmine 5-6 mg iv (n = 3), neostigmine 0-5-1-5 mg iv (n = 5) or neostigmine 30 mg orally (n = 1). The patients had more than 25% decrement in the deltoid muscle and had not been treated with cholinesterase inhibitors previously.
The investigation was performed in the morning before the patients had left the bed or with the patients seated in a comfortable chair after minimal preceeding exercise. The patients rested completely for 60 min before the drug was given. Throughout the investigation a thermostatically controlled heating lamp was used to keep a constant skin temperature of 32°C.
Recording of the muscle response was made with surface electrodes, one over the midpoint of the deltoid muscle, the other over the acromion. Stimulation was made with surface electrodes over Erb's point with a stimulation strength set to 25% above that giving maximal amplitude, with a duration of 0-1 ms and a frequency of 2 Hz. By means of a computer (LSI 11/23) the negative amplitude and area under the whole signal was measured. The relative difference between the first and the fourth response was measured for these two parameters. The area measurement was added as a test of the recording quality. Normally the two parameters show a good correlation but in cases of artifacts they usually differ and the test has to be repeated. In the following only the amplitude results will be given. Measurements were made every tenth minute during 30-60 minutes before the administration of the drugs and then every fifth minute after intravenous and every tenth minute after oral administration for another 3 to 5 hours. (table 3) . The predose plasma concentration of pyridostigmine was also higher in the older patients (p < 0-01). In this group severe generalised myasthenia was more frequent (tables 1 and 3).
In the 11 patients concomitantly treated with atropine the mean maximal plasma concentration was significantly higher (139 + 30, n = 11) than in the patients not treated with atropine (78 ± 26, n = 9).
In the three patients on prednisone the plasma concentration of pyridostigmine did not seem to differ from that in other patients on the same daily dose of pyridostigmine. Influences of the other medications are difficult to assess but there were no apparent systematic variations.
Neostigmine Four patients were treated simultaneously with neostigmine and pyridostigmine and the plasma concentration of neostigmine ranged from 3-6 ng/ml. In fig 3 (a-c) the log plasma concentrations versus the effect on the decrement (moving averages) are shown. As can be seen there was a direct linear relation between log plasma concentration and effect only for the oral data (figs 2, 3c) while the iv data are more complex. A positive linear correlation (nega- Pyridostigmine I V tive slope) between log plasma concentration following iv injection and effect is seen when the plasma concentration is lower than 30-60 ng/ml for pyridostigmine and about 5-15 ng/ml for neostigmine. Higher concentrations give a negative correlation (positive slope) between plasma concentration and effect on muscle decrement. In one patient (ME, fig  3b) with a low clearance of neostigmine there was a negative correlation still after 3*5 hours; at this time the plasma concentration was above 6 ng/ml. In one patient (GA, fig 3b) maximal effect on decrement was seen at a very high plasma concentration of neostigmine (100 ng/ml), whereas following pynrdostigmine the corresponding effect was seen at a plasma concentration similar to what was found in the other patients. On maintenance therapy with pyridostigmine the intraindividual variations in plasma concentration of the drug were rather small during a 3 hour dose interval. This is in agreement with results earlier obtained.7 The limited variation in steady-state concentration of pyridostigmine in spite of the short half-life is probably explained by the slow absorption from the gastrointestinal tract earlier shown.7
Much larger variations in pyridostigmine concentration during a dose interval have been reported'0 and an enterohepatic circulation has been postulated due to an observed second peak in the plasma concentration curve. In the present study no such phenomenon was seen. In view of the lag-time together with food intake7 the "second peak" may be the plasma concentration peak of the tablet before.
The interindividual differences in steady-state plasma concentration of pyridostigmine between myasthenic patients on maintenance therapy were considerable (table 1) which is in agreement with earlier reports.71 The interindividual variations were larger and the predose plasma concentrations higher in the older patients who had a higher mean daily dose (table 3) . The relation between dose and plasma concentration is, however, complex and the possible influence of a number of factors as, for example, age, severity of disease, impaired kidney function and other medications cannot be determined in any detail due to the relatively small number of patients. It is known that pyridostigmine is predominantly eliminated in the urine and a decreased renal function could lower the total clearance of the drug. "'-'3 In the older age group more severe forms of the disease were found (tables 1 and 2) which may explain the use of higher doses of cholinesterase inhibitors. This is in accordance with the findings of White et al'0 who observed higher plasma concentrations of pyridostigmine in "poorly controlled patients" than in "well controlled".
EFFECT OF OTHER DRUGS
It has earlier been shown that the oral bioavailability of pyridostigmine is decreased in patients on steroids'0 but in the present investigation no influence of steroid therapy could be seen. Chan and Calvey'2 suggested that a competition for the renal excretion could exist between pyridostigmine and basic drugs. In our patients treated with atropine the mean maximal plasma concentration of pyridostigmine was much higher than in patients not taking atropine. This is probably not a result of pharmacokinetic interaction but of increased need for anticholinergic therapy in patients having higher plasma concentration of pyridostigmine and thus more side-effects.
The plasma concentrations of neostigmine are in the same range (3-6 ng/ml) as earlier reported following 90-150 mg orally.6 Theoretically the simultaneous therapy with neostigmine and pyridostigmine could give rise to drug-drug interactions during absorption, or by competition for enzymatic degradation or renal secretion as has been postulated. '2 1' In the present study no pharmacokinetic interaction could be detected.
PHARMACOKINETIC DATA There were rather large interindividual variations in clearance and terminal half-lives of pyridostigmine and neostigmine. The mean half-lives of the two drugs did not differ significantly. In the crossover experiment (patients GA, KL and MB), however, there was a 2:1 relation between the half-life of pyridostigmine (1-05 hours) compared with neostigmine (0.48 hours) while the total clearance was similar. This is explained by the much lower volume of distribution for neostigmine (0.67 11kg) compared with pyridostigmine (1-76 1/kg). The results are similar to those earlier found.67
The rationale of parallel therapy with pyridostigmine and neostigmine with very much the same pharmacodynamic and pharmacokinetic profile could be questionable. The higher oral bioavailability and the slightly longer terminal half-life favour the use of pyridostigmine as monotherapy.
DOSE-EFFECT STUDIES
A previous study of nine myasthenic patients who were examined neurologically at 1/2 hour intervals after administration of oral pyridostigmine showed improved motor performance which in most patients seemed to be positively related to the time-course of pyridostigmine plasma concentration.' However, clinical evaluation of the effect involves many problems; for example standardised tests of power and fatigue in several muscles are time consuming and necessitate rather long rest between each examination. Furthermore, myasthenic weakness typically varies considerably between different muscle groups in the same patient and may be restricted to a few muscles. A certain dose of anticholinesterase may improve function of some muscles but not others. The difficulties encountered in these types of studies were recently illustrated by Davison et all5 who found that only two out of nine myasthenic patients on their normal drug regime showed a significant correlation between plasma levels of pyridostigmine and a global evaluation of muscle functions.
